Published in FASEB J on August 01, 1999
Vaccination with genetically engineered allergens prevents progression of allergic disease. Proc Natl Acad Sci U S A (2004) 1.53
Crystal structure and activities of EXPB1 (Zea m 1), a beta-expansin and group-1 pollen allergen from maize. Proc Natl Acad Sci U S A (2006) 1.37
Crystal structure of a dimerized cockroach allergen Bla g 2 complexed with a monoclonal antibody. J Biol Chem (2008) 1.35
In vitro evolution of allergy vaccine candidates, with maintained structure, but reduced B cell and T cell activation capacity. PLoS One (2011) 0.92
Structural functionality, catalytic mechanism modeling and molecular allergenicity of phenylcoumaran benzylic ether reductase, an olive pollen (Ole e 12) allergen. J Comput Aided Mol Des (2013) 0.80
Structure and functional features of olive pollen pectin methylesterase using homology modeling and molecular docking methods. J Mol Model (2012) 0.80
Comparisons of Allergenic and Metazoan Parasite Proteins: Allergy the Price of Immunity. PLoS Comput Biol (2015) 0.79
Mapping of IgE-binding regions on recombinant Cyn d 1, a major allergen from Bermuda Grass Pollen (BGP). Clin Mol Allergy (2009) 0.77
High-density IgE recognition of the major grass pollen allergen Phl p 1 revealed with single-chain IgE antibody fragments obtained by combinatorial cloning. J Immunol (2015) 0.76
New strategies for allergen T cell epitope identification: going beyond IgE. Int Arch Allergy Immunol (2014) 0.76
Anti-idiotypic Fab Fragments Image a Conserved N-terminal Epitope Patch of Grass Pollen Allergen Phl p 1. Open Allergy J (2011) 0.75
Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res (2001) 4.87
Deletion of the alternative sigma factor sigmaB in Staphylococcus aureus reveals its function as a global regulator of virulence genes. J Bacteriol (1998) 4.18
Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest (2007) 3.58
An essential protease involved in bacterial cell-cycle control. EMBO J (1998) 3.07
The Fc receptor for IgG on human natural killer cells: phenotypic, functional, and comparative studies with monoclonal antibodies. J Immunol (1984) 2.70
Evidence for high-energy extraterrestrial neutrinos at the IceCube detector. Science (2013) 2.56
Practical guide to skin prick tests in allergy to aeroallergens. Allergy (2011) 2.51
MDR1 gene expression and treatment outcome in acute myeloid leukemia. J Natl Cancer Inst (1991) 2.50
Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells. Leukemia (2008) 2.44
A shared antigenic determinant between natural killer cells and nervous tissue. Nature (1984) 2.24
Influence of implantable cardioverter-defibrillators on the long-term prognosis of survivors of out-of-hospital cardiac arrest. Circulation (1993) 2.20
Antibodies induced with recombinant VP1 from human rhinovirus exhibit cross-neutralisation. Eur Respir J (2010) 2.19
Allergic Rhinitis and its Impact on Asthma (ARIA): achievements in 10 years and future needs. J Allergy Clin Immunol (2012) 2.17
Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodies. Clin Exp Allergy (2003) 2.08
HIV-1-induced thymocyte depletion is associated with indirect cytopathogenicity and infection of progenitor cells in vivo. Immunity (1995) 2.07
First observation of PeV-energy neutrinos with IceCube. Phys Rev Lett (2013) 2.00
Preventing recurrent depression using cognitive therapy with and without a continuation phase: a randomized clinical trial. Arch Gen Psychiatry (2001) 1.93
The gene coding for the major birch pollen allergen Betv1, is highly homologous to a pea disease resistance response gene. EMBO J (1989) 1.93
Treatment of atypical depression with cognitive therapy or phenelzine: a double-blind, placebo-controlled trial. Arch Gen Psychiatry (1999) 1.90
Role of the sympathetic nervous system in the genesis of ventricular arrhythmia. Circulation (1990) 1.86
Factors responsible for differences between asymptomatic subjects and patients presenting an IgE sensitization to allergens. A GA2LEN project. Allergy (2006) 1.84
Immunological changes during specific immunotherapy of grass pollen allergy: reduced lymphoproliferative responses to allergen and shift from TH2 to TH1 in T-cell clones specific for Phl p 1, a major grass pollen allergen. Clin Exp Allergy (1997) 1.80
Microinjected profilin affects cytoplasmic streaming in plant cells by rapidly depolymerizing actin microfilaments. Curr Biol (1994) 1.70
Allergen immunotherapy: therapeutic vaccines for allergic diseases. World Health Organization. American academy of Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol (1998) 1.70
Late reactions to the patch-test preparations para-phenylenediamine and epoxy resin: a prospective multicentre investigation of the German Contact Dermatitis Research Group. Br J Dermatol (2006) 1.67
Mucosal tolerance as therapy of type I allergy: intranasal application of recombinant Bet v 1, the major birch pollen allergen, leads to the suppression of allergic immune responses and airway inflammation in sensitized mice. Clin Exp Allergy (2002) 1.63
Identification of profilin as a novel pollen allergen; IgE autoreactivity in sensitized individuals. Science (1991) 1.62
AllergoOncology: the role of IgE-mediated allergy in cancer. Allergy (2008) 1.59
The high affinity IgE receptor (Fc epsilon RI) mediates IgE-dependent allergen presentation. J Immunol (1995) 1.59
Basophils are not the key antigen-presenting cells in allergic patients. Allergy (2012) 1.57
Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group. Leukemia (2012) 1.57
The profilin multigene family of maize: differential expression of three isoforms. Plant J (1993) 1.56
Prevention of latex allergy by selection of low-allergen gloves. Clin Exp Allergy (2000) 1.55
Vaccines for birch pollen allergy based on genetically engineered hypoallergenic derivatives of the major birch pollen allergen, Bet v 1. Clin Exp Allergy (2004) 1.55
Vaccination with genetically engineered allergens prevents progression of allergic disease. Proc Natl Acad Sci U S A (2004) 1.53
Dissection of immunoglobulin E and T lymphocyte reactivity of isoforms of the major birch pollen allergen Bet v 1: potential use of hypoallergenic isoforms for immunotherapy. J Exp Med (1996) 1.51
The recombinant allergen-based concept of component-resolved diagnostics and immunotherapy (CRD and CRIT). Clin Exp Allergy (1999) 1.51
Diagnosis of mastocytosis: general histopathological aspects, morphological criteria, and immunohistochemical findings. Leuk Res (2001) 1.48
Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q. Leukemia (2010) 1.48
Prophylactic and therapeutic vaccination with carrier-bound Bet v 1 peptides lacking allergen-specific T cell epitopes reduces Bet v 1-specific T cell responses via blocking antibodies in a murine model for birch pollen allergy. Clin Exp Allergy (2014) 1.45
Inhalation scintigraphy with iodine-123-labeled interferon gamma-1b: pulmonary deposition and dose escalation study in healthy volunteers. J Nucl Med (1997) 1.44
Formaldehyde-induced anaphylaxis after dental treatment? Contact Dermatitis (1991) 1.44
A comparative study on demographic, hematological, and cytogenetic findings and prognosis in acute myeloid leukemia with and without leukemia cutis. Ann Hematol (2002) 1.44
Systemic mastocytosis with associated clonal haematological non-mast cell lineage diseases: a histopathological challenge. J Clin Pathol (2004) 1.43
Comorbidity as prognostic variable in MDS: comparative evaluation of the HCT-CI and CCI in a core dataset of 419 patients of the Austrian MDS Study Group. Ann Oncol (2009) 1.43
Analysis of the localization of STE6/CFTR chimeras in a Saccharomyces cerevisiae model for the cystic fibrosis defect CFTR delta F508. Mol Microbiol (1996) 1.42
Marker of peripheral blood granulocytes and monocytes of man recognized by two monoclonal antibodies VEP8 and VEP9 involves the trisaccharide 3-fucosyl-N-acetyllactosamine. Eur J Immunol (1983) 1.41
Venoconstrictive thigh cuffs impede fluid shifts during simulated microgravity. Aviat Space Environ Med (1998) 1.40
Effects of dental amalgam and its components of histamine release from human basophils and tissue mast cells. Wien Klin Wochenschr (1998) 1.39
Profilins constitute a novel family of functional plant pan-allergens. J Exp Med (1992) 1.35
Immunosuppression and atypical infections in CML patients treated with dasatinib at 140 mg daily. Eur J Clin Invest (2009) 1.32
Peripheral blood dendritic cells express Fc epsilon RI as a complex composed of Fc epsilon RI alpha- and Fc epsilon RI gamma-chains and can use this receptor for IgE-mediated allergen presentation. J Immunol (1996) 1.30
Variability of IgE reactivity profiles among European mite allergic patients. Eur J Clin Invest (2008) 1.29
Diagnostic value of immunostaining for tryptase in patients with mastocytosis. Am J Surg Pathol (1998) 1.28
Modulation of IgE reactivity of allergens by site-directed mutagenesis: potential use of hypoallergenic variants for immunotherapy. FASEB J (1998) 1.28
Shiitake dermatitis. Br J Dermatol (2003) 1.27
Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): a multicenter study. Leukemia (2012) 1.27
Cloning and sequencing of Mal d 1, the major allergen from apple (Malus domestica), and its immunological relationship to Bet v 1, the major birch pollen allergen. Biochem Biophys Res Commun (1995) 1.25
A monoclonal antibody against a surface antigen shared by human large granular lymphocytes and granulocytes. J Immunol (1982) 1.24
MeDALL (Mechanisms of the Development of ALLergy): an integrated approach from phenotypes to systems medicine. Allergy (2011) 1.22
Prognostic impact of age and gender in 897 untreated patients with primary myelodysplastic syndromes. Ann Oncol (2009) 1.22
Conversion of the major birch pollen allergen, Bet v 1, into two nonanaphylactic T cell epitope-containing fragments: candidates for a novel form of specific immunotherapy. J Clin Invest (1997) 1.22
Nonanaphylactic synthetic peptides derived from B cell epitopes of the major grass pollen allergen, Phl p 1, for allergy vaccination. FASEB J (2001) 1.21
IgE and IgG antibodies of patients with allergy to birch pollen as tools to define the allergen profile of Betula verrucosa. Allergy (1989) 1.21
Developments in allergen-specific immunotherapy: from allergen extracts to allergy vaccines bypassing allergen-specific immunoglobulin E and T cell reactivity. Clin Exp Allergy (2010) 1.20
Important research questions in allergy and related diseases: nonallergic rhinitis: a GA2LEN paper. Allergy (2008) 1.20
The molecular basis for allergen cross-reactivity: crystal structure and IgE-epitope mapping of birch pollen profilin. Structure (1997) 1.18
Morphologic properties of neoplastic mast cells: delineation of stages of maturation and implication for cytological grading of mastocytosis. Leuk Res (2001) 1.17
Induction of antibody responses to new B cell epitopes indicates vaccination character of allergen immunotherapy. Eur J Immunol (1999) 1.17
Clinical and biologic diversity of leukemias occurring in patients with mastocytosis. Leuk Lymphoma (2000) 1.16
Induction of Fc epsilon R2/CD23 on human epidermal Langerhans cells by human recombinant interleukin 4 and gamma interferon. J Exp Med (1989) 1.16
Heterogeneity of commercial timothy grass pollen extracts. Clin Exp Allergy (2008) 1.16